Dernières nouvelles pour Illumina (NASDAQ:ILMN) Stock

Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina Inc

Illumina Inc COM-WHEN ISSUED

ILLUMINA ORD

In the preceding three months, 14 analysts have released ratings for Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $166.5, a high estimate of $252.00, and a low estimate of $124.00. This current average represents a 0.1% decrease from the previous average price target of $166.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1728590423_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Illumina by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$252.00</td>
<td>$252.00</td>
</tr>
<tr>
<td>Jasper Hellweg</td>
<td>Argus Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Narumi Nakagiri</td>
<td>Daiwa Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$154.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$164.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$144.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$242.00</td>
<td>$242.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$126.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$155.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$242.00</td>
<td>$242.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$124.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$133.00</td>
<td>$131.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Illumina. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Illumina's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Illumina's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Illumina analyst ratings.</a>
<h2>Get to Know Illumina Better</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>Understanding the Numbers: Illumina's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Illumina's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -5.44%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Illumina's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -178.78%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Illumina's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -55.45%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Illumina's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -24.66%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Illumina's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.03, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ILMN

Decoding 14 Analyst Evaluations For Illumina

RBC Capital analyst Conor McNamara reiterates Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Outperform and maintains $252 price target.

News

Price Target

Reiteration

RBC Capital Reiterates Outperform on Illumina, Maintains $252 Price Target

Rumors

Trading Ideas

Watching 10x Genomics; Shares Move Higher As Illumina Announces It Is Launching Compact, Low-Cost Gene Sequencing Devices

Designed to make next-generation sequencing accessible to more labs
With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries
SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, today unveiled its MiSeq&#x2122; i100 Series of sequencing systems, delivering unparalleled benchtop speed and simplicity to advance next-generation sequencing (NGS) for labs.
&nbsp;
The two new benchtop instruments, MiSeq i100 and MiSeq i100 Plus Systems, will empower customers to unlock&nbsp;powerful insights through an affordable, comprehensive solution that is simple to understand and use, even for those with limited NGS expertise. Room-temperature storage and shipping enable labs to sequence on demand, with no delays for thaw time, and same-day sample-to-analysis.

Illumina Unveils MiSeq i100 Series Sequencing Systems To Advance Next Generation Sequencing For Labs; US List Price Is $49,000 & $109,000 For MiSeq i100 Plus; Available For Global Shipping In 2025

Illumina's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NYSE">ILMN</a>) short percent of float has risen 8.81% since its last report. The company recently reported that it has 4.88 million shares sold short, which is 3.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.47 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Illumina Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728478826_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Illumina has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Illumina's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Illumina's peer group average for short interest as a percentage of float is 5.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Illumina?

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 11.9% on an annualized basis producing an average annual return of 20.33%. Currently, Illumina has a market capitalization of $20.38 billion. 
Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $4,050.72 today based on a price of $127.97 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727805627_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years

Vanda Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vnda#NASDAQ">VNDA</a>) announced that the FDA issued a complete response letter&nbsp;to its new drug application (NDA) seeking approval for its pipeline candidate, tradipitant for the treatment of symptoms in gastroparesis.
Shares of the company were down 6.1% on Sept. 19 following the announcement of the news.
Marked by delayed gastric emptying, gastroparesis is a serious condition that slows down the stomach&#39;s ability to empty its contents. The FDA has not approved any effective medicine for treating gastroparesis in more than 40 years.
Year to date, shares of Vanda have increased 10.2% compared with the industry&#39;s rise of 0.4%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/4a/78570.jpg?v=840412258" />
Image Source: Zacks Investment Research
<h2>More on FDA&#39;s CRL for VNDA&#39;s Tradipitant</h2>
Per the CRL, the FDA called for Vanda to conduct additional studies on tradipitant with a design that was inconsistent with the advice of key experts in the field and not appropriate based on the scientific understanding of the disease.
Also, per management, the FDA delayed its decision by more than 185 days and failed to meet the requirements specified by the Food Drug and Cosmetic Act (FDCA).
Notably, the FDCA requires that the FDA review an NDA and provide either an approval or a possible hearing within 180 days of the filing. The FDA failed to do either.
Per the company, it had time and again asked the FDA to hold an advisory committee meeting to discuss the NDA for tradipitant while the regulatory body declined.
Several patients treated with tradipitant have now filed a Citizen Petition pleading with the regulatory body to approve tradipitant for the treatment of gastroparesis.
<h2>VNDA&#39;s Development Plans for Tradipitant</h2>
Despite the FDA declining to approve tradipitant for treating symptoms in gastroparesis, the company will continue to pursue the marketing approval for tradipitant in the given indication.
Apart from gastroparesis, VNDA is also developing tradipitant for preventing vomiting induced by motion sickness.
In May 2024, the company announced positive data from a second phase III study that investigated tradipitant for preventing vomiting induced by motion sickness.
Vanda plans to submit an NDA for tradipitant to the FDA for the treatment of motion sickness later in 2024.
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Vanda currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>), Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.84 to $3.63. Earnings per share estimates for 2025 have improved from $3.22 to $4.43. Year to date, shares of ILMN have lost 3.5%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $2.09 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 48.7%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, with the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.33 to 28 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.14. Year to date, shares of FULC have plunged 48.9%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2339326/vnda-stock-down-as-fda-rejects-nda-for-tradipitant-in-gastroparesis?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2339326">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

Penny Stocks

Small Cap

Management

Markets

General

FULC

KRYS

VNDA

VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$65.0K</td>
<td>37.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>814</td>
<td>482</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$130.00</td>
<td>$25.3K</td>
<td>972</td>
<td>303</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$196.0K</td>
<td>7</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$62.50</td>
<td>$90.0K</td>
<td>1.0K</td>
<td>200</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$128.00</td>
<td>$32.6K</td>
<td>6</td>
<td>200</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$105.3K</td>
<td>561</td>
<td>174</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$155.00</td>
<td>$55.5K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$380.00</td>
<td>$98.7K</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>RPRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$50.2K</td>
<td>43</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 485 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $65.0K, with a price of $325.0 per contract. There were 37533 open contracts at this strike prior to today, and today 2165 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on September 27, 2024. Parties traded 104 contract(s) at a $70.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $252.0 per contract. There were 814 open contracts at this strike prior to today, and today 482 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with bullish sentiment. It expires in 30 day(s) on October 18, 2024. Parties traded 59 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $430.0 per contract. There were 972 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we notice a put option trade that happens to be neutral, expiring in 485 day(s) on January 16, 2026. This event was a transfer of 200 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $196.0K, with a price of $980.0 per contract. There were 7 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option trade that happens to be bullish, expiring in 121 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $90.0K, with a price of $450.0 per contract. There were 1039 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with bearish sentiment. It expires in 2 day(s) on September 20, 2024. Parties traded 102 contract(s) at a $128.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $320.0 per contract. There were 6 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 121 day(s) on January 17, 2025. Parties traded 70 contract(s) at a $315.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $105.3K, with a price of $1505.0 per contract. There were 561 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option trade with bullish sentiment. It expires in 211 day(s) on April 17, 2025. Parties traded 150 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $55.5K, with a price of $370.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 275 day(s) on June 20, 2025. This event was a transfer of 30 contract(s) at a $380.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $3290.0 per contract. There were 10 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• For RPRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), we notice a call option trade that happens to be bullish, expiring in 211 day(s) on April 17, 2025. This event was a transfer of 54 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 43 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALGN

AMGN

EXAS

MRNA

RPRX

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

Shares of Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>) plunged 61.1% on Sept. 12 after the company announced disappointing top-line data from the phase III REACH study, which evaluated its pipeline candidate, losmapimod, for treating patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating disease.
Currently, there are no treatments approved for the given indication.
The study did not meet its primary endpoint as treatment with losmapimod failed to demonstrate a change from baseline in relative surface area (RSA), a measure of reachable workspace (RWS), compared with placebo at week 48.
The study also failed to achieve nominal statistical significance on the secondary endpoints.
Year to date, shares of Fulcrum have plunged 49% compared with the industry&#39;s decline of 0.8%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ab/77679.jpg?v=1785498249" style="height:371px; width:592px" />
Image Source: Zacks Investment Research
<h2>Data From FULC&#39;s REACH study</h2>
Data from the REACH study showed that treatment with losmapimod led to a 0.013 improvement in RSA compared to a 0.010 improvement in RWS for patients who received a placebo at week 48. This was the study&#39;s primary endpoint.
Also, patients receiving losmapimod demonstrated an increase of 0.42% in muscle fat infiltration while an increase of 0.57% in MFI was observed for patients who received placebo at week 48.
Meanwhile, patients who were treated with losmapimod demonstrated a 9.63% improvement in abductor strength compared with a 2.24% improvement in the placebo arm.
There were no statistically significant differences observed in the two patient-reported outcomes secondary endpoints of the REACH study.
Following the disappointing data observed in the REACH study, FULC decided to stop the further development of losmapimod in FSHD.
<h2>What&#39;s Next for FULC in Terms of Pipeline Development</h2>
Fulcrum is developing another pipeline candidate, pociredir, in an early-stage study for treating patients with sickle cell disease, an inherited blood disorder. The phase Ib PIONEER study evaluates pociredir in SCD.
The FDA has already granted a Fast Track designation and Orphan Drug designation to pociredir for the treatment of patients with SCD.
SCD has a significant unmet medical need, and if successfully developed and upon potential approval, pociredir has the potential to boost FULC&#39;s prospects in the days ahead.
As of June 30. 2024, Fulcrum had $273.8 million in cash, cash equivalents and marketable securities. The company plans to use the funds to advance pociredir in the treatment of SCD and other pipeline development activities.
<h2>Zacks Rank &amp; Other Stocks to Consider</h2>
Fulcrum currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the biotech sector are Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) and Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>), each sporting a Zacks Rank #1 at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.43. Year to date, shares of ILMN have lost 9.3%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 57.7%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
<a href="https://www.zacks.com/stock/news/2336049/fulc-stock-falls-as-muscle-disorder-study-misses-primary-goal?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2336049">To read this article on Zacks.com click here.</a>

Large Cap

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 11.63% on an annualized basis producing an average annual return of 19.91%. Currently, Illumina has a market capitalization of $19.94 billion. 
Buying $1000 In ILMN: If an investor had bought $1000 of ILMN stock 20 years ago, it would be worth $37,705.05 today based on a price of $125.16 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726083015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth $38,000 Today

Shares of Immunovant (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imvt#NASDAQ">IMVT</a>) are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves&#39; Disease.
<h2>IMVT&#39;s Batoclimab Shows Superior Efficacy in GD Patients</h2>
The enrolled patient population of the phase IIa study of batoclimab comprised uncontrolled GD patients who were hyperthyroid despite anti-thyroid drugs therapy.&nbsp;Patients were then treated with the high batoclimab dose, 680 mg weekly subcutaneous injection, for 12 weeks, followed by another 12 weeks of lower batoclimab dose, 340 mg weekly SC.
The data showed that treatment with the batoclimab 680 mg dose led to a mean Immunoglobin G (IgG) reduction of 77%, translating to a Response rate of 76% in the GD patient population after 12 weeks. Additionally, it was observed that at the end of the first 12 weeks, 56% of the patients treated with the high-dose of the candidate achieved an ATD-Free Response.
During the next 12 weeks of treatment with the batoclimab 340 mg dose, the mean IgG&nbsp;level was further reduced by 65%, with a correspondingly lower responder rate of 68%. Additionally, the ATD-Free Response rate dropped to 36% in the second 12 weeks.
Patients who experienced at least a 70% IgG reduction by the end of the study had an ATD-Free Response rate nearly three times higher than those who did not (60% and 23%, respectively).
Year to date, shares of Immunovant have plunged 19.2% compared with the industry&#39;s 2.8% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/cd/76945.jpg?v=1496532795" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
Along with the data readout, Immunovant also revealed data from multiple proprietary market research studies, highlighting a persistent unmet need among patients treated with ATDs who are either intolerant to, uncontrolled or have relapsed after treatment with the same.&nbsp;&nbsp;
Per IMVT, real-world claims data shows that 25-30% of GD patients remain uncontrolled on ATDs each year, with few treatment options available. This presents a valuable commercial opportunity for the company with little competition.
<h2>IMVT&#39;s Future Development Plans in Autoimmune Diseases</h2>
Leveraging the encouraging results from the phase IIa GD study ofbatoclimab, Immunovant is currently gearing up to initiate a pivotal study of its lead candidate, IMVT-1402, a novel and fully-human monoclonal antibody, for the same indication by the end of 2024.
In the press release, the company has also announced that it has aligned with the FDA regarding the impending pivotal study design and secured investigational new drug application clearance for IMVT-1402 to treat GD.
Apart from the GD study, separate mid to late-stage studies are also currently ongoing, evaluating batoclimab for the treatment of other autoimmune indications, like Myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and thyroid eye disease. Subject to positive data from these studies, Immunovant plans to study IMVT-1402 for each of the above indications.
The company is on track to initiate four to five potentially registrational programs for IMVT-1402 over the next fiscal year (ending March 31, 2025). Over the next two fiscal years, the company plans to initiate studies in a total of 10 indications for IMVT-1402. The company also expects to achieve financial efficiencies in its IMVT-1402 development program by leveraging the data already available from batoclimab studies.
<div class="chart_embed">
<h2>Immunovant, Inc. Price and Consensus</h2>
<img alt="Immunovant, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/9c/1725883442.png" style="height:310px; width:600px" title="" />
Immunovant, Inc. price-consensus-chart | Immunovant, Inc. Quote
</div>
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Immunovant currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are&nbsp;Illumina, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>),&nbsp;Krystal Biotech, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and&nbsp;Fulcrum Therapeutics, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 10,7%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 48.5%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 26.5%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2333347/imvt-stock-up-on-upbeat-data-from-graves-disease-study-of-batoclimab?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2333347">To read this article on Zacks.com click here.</a>

Mid Cap

IMVT

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

Shares of Corcept Therapeutics Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cort#NASDAQ">CORT</a>) have gained 46.2% in the past six months against the industry&#39;s decline of 2%.
The company&#39;s sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing&#39;s syndrome, has been performing well. The drug has been witnessing a strong demand in the past couple of quarters.
The company is also making good progress with its promising set of pipeline candidates.
<h2>Factors Driving CORT Stock in the Given Time Frame</h2>
Corcept has made steady progress with the development of its lead pipeline candidate, relacorilant, which is being evaluated in the phase III GRACE study for the treatment of Cushing&#39;s syndrome, also known as hypercortisolism.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/1c/76375.jpg?v=14044768" />
Image Source: Zacks Investment Research
The GRACE study comprises two parts &mdash; the open-label portion and the randomized withdrawal phase. In May 2024, CORT announced that the GRACE study met the primary endpoint in the randomized withdrawal phase. Data from the same showed that patients who were treated with relacorilant experienced loss of blood pressure control, the study&#39;s primary endpoint, versus placebo.
In April, the company announced data from the open-label phase of the GRACE study, which showed that treatment with relacorilant led to clinically meaningful and statistically significant improvements in hypertension, hyperglycemia, as well as other symptoms.
Per management, the GRACE study meeting the primary endpoint is a significant step forward in the development path for relacorilant as a treatment for Cushing&#39;s syndrome. A new drug application for relacorilant is likely to be submitted in the fourth quarter of 2024.
The candidate is also being evaluated in the phase III GRADIENT study for treating patients whose Cushing&#39;s syndrome is caused by adrenal adenoma. Data from the same is expected in the fourth quarter of 2024.
Corcept is also studying relacorilant in combination with other therapies for treating different cancer indications. The successful development of relacorilant will be an added boost to the company.
<h2>Korlym Drives Revenues for CORT</h2>
Corcept&#39;s top line solely comprises product sales from Korlym. The drug has been a consistent revenue driver for the company since approval. Sales of the drug increased 39.1% year over year to $310.6 million in the first half of 2024, owing to the strong demand and a record number of patients receiving the medication.
The company increased its annual revenue guidance for Korlym concurrently with second-quarter results. The company now expects total revenues in the range of $640-$670 million compared with the earlier projection of $620-$650 million.
The strong demand for Korlym is likely to continue the momentum for Corcept for the remainder of 2024. Also, a potential approval for relacorilant should help the company address a broader patient population, which should push the stock upward in the future quarters.
<div class="chart_embed">
<h2>Corcept Therapeutics Incorporated Price</h2>
<img alt="Corcept Therapeutics Incorporated Price" src="https://staticx-tuner.zacks.com/images/charts/2c/1725369636.png" style="height:251px; width:538px" title="" />
Corcept Therapeutics Incorporated price | Corcept Therapeutics Incorporated Quote
</div>
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Corcept currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the drug/biotech sector are Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>), Bioventus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bvs#NASDAQ">BVS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 5.6%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Bioventus&#39; 2024 earnings per share have increased from 27 cents to 40 cents. Earnings per share estimates for 2025 have improved from 43 cents to 45 cents. Year to date, shares of BVS have risen 90.7%.
BVS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 102.86%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 26.7%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2330901/corcept-shares-rise-more-than-45-in-six-months-here-s-why?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2330901">To read this article on Zacks.com click here.</a>

CORT

Corcept Shares Rise More Than 45% in Six Months: Here's Why

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>) were down 8.5% on Aug. 30, after the company announced detailed data from the phase III HELIOS-B, which evaluated its investigational RNAi therapeutic, Amvuttra (vutrisiran) for an expanded indication.
The HELIOS-B study is seeking to expand the label of Amvuttra for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Per the company, the HELIOS-B study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events in the overall population as well as the monotherapy population.
However, as a component of the primary endpoint, treatment with vutrisiran led to a 30% reduction in mortality in the monotherapy population in the double-blind period. Per management, this reduction was non-significant.
This might have hurt investors&#39; sentiments and resulted in the stock going down.
<h2>ALNY Stock Outperforming Industry</h2>
Shares of Alnylam have gained 37.3% so far this year compared with the industry&#39;s growth of 0.6%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/42/76266.jpg?v=875498674" />
Image Source: Zacks Investment Research
Please note that vutrisiran is already approved in the United States for the treatment of adult patients with polyneuropathy of hereditary ATTR amyloidosis. This is also approved in the European Union for the same indication in adult patients with stage 1 or stage 2 polyneuropathy. Vutrisiran is marketed under the trade name Amvuttra in the United States and Europe.
In June 2024, Alnylam reported encouraging data from the phase III HELIOS-B study evaluating vutrisiran for the treatment of patients with ATTR amyloidosis with cardiomyopathy. Shares of the company soared on this news.
The phase III HELIOS-B study enrolled 655 adult patients with ATTR amyloidosis (hereditary or wild-type) with cardiomyopathy who were divided equally to receive vutrisiran 25mg or placebo subcutaneously once every three months for up to 36 months.
Alnylam is gearing up to proceed with global regulatory submissions, including filing a supplemental new drug application for vutrisiran with the FDA using a Priority Review Voucher later in 2024.
<h2>Amvuttra, a Key Revenue Driver for ALNY</h2>
Amvuttra is currently the top contributor to Alnylam&#39;s top line. This drug generated sales worth $425.4 million in the first half of 2024, increasing 82% year over year on a reported basis. The encouraging uptake of the drug is driven by new patients starting treatment as well as patients switching from ALNY&#39;s Onpattro(patisiran).
Onpattro is also approved in the United States and European Union to treat ATTR amyloidosis in adults.
If approved forthe new indication, Alnylam believes that vutrisiran has the potential to become the new standard of care for the treatment of ATTR amyloidosis with cardiomyopathy. This is likely to boost sales further and will expand the eligible patient population for the drug in future quarters.
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Alnylam currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>), Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 5.6%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 57.3%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 26.7%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2330592/alny-down-despite-positive-data-from-heart-disease-drug-study?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2330592">To read this article on Zacks.com click here.</a>

ALNY

ALNY Down Despite Positive Data From Heart Disease Drug Study

Provider of DNA sequencing and array-based technologies, Illumina, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) said it welcomes the European Court of Justice&#8217;s (ECJ&#8217;s) judgment ruling that the European Commission did not have jurisdiction over Illumina&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40680742/european-court-of-justice-rules-in-favor-of-illumina-in-jurisdictional-appeal" rel="noreferrer noopener">acquisition of GRAIL</a>.
The judgment confirms Illumina&#8217;s longstanding view that the European Commission exceeded its authority by asserting jurisdiction <a target="_blank" href="https://www.benzinga.com/markets/equities/23/12/36202820/illumina-versus-european-commission-legal-battle-over-grail-acquisition-reaches-critical-stage" rel="noreferrer noopener">over this merger</a>.
The basis for the&nbsp;$476.96 million (432 million euro)&nbsp;fine has been removed and will no longer be payable.
Following Illumina&#8217;s spinoff of GRAIL Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) in&nbsp;June 2024, GRAIL is now an <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/06/39474696/once-valued-at-around-7b-cancer-blood-test-developer-grail-to-kickstart-trading-on-nasdaq" rel="noreferrer noopener">independent public company</a>.
Nearly four years after pitching for&nbsp;Grail,&nbsp;Illumina finally separated the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/b39465729/grail-to-begin-trading-on-the-nasdaq-stock-exchange" rel="noreferrer noopener">cancer blood test developer</a>.&nbsp;
In July 2021, Illumina said it was committed to <a href="https://www.benzinga.com/government/21/07/22128324/illumina-grail-8b-merger-hit-by-european-commissions-in-depth-investigation" target="_blank" rel="noreferrer noopener">re-acquiring Grail</a>. Illumina maintains a minority share of 14.5% in GRAIL.
&#8220;The Commission is not authorized to encourage or accept referrals of proposed concentrations without a European dimension from national competition authorities where those authorities are not competent to examine those proposed concentrations under their own national law,&#8221; Reuters highlighted, citing CJEU judges.
In the U.S., the FTC Commissioners dismissed the case against Illumina and GRAIL on&nbsp;August 15, 2024, following the spinoff of GRAIL, thus ending the US proceedings.
In a setback for EU antitrust regulators, in March, an adviser to Europe&#8217;s top court criticized the decision to block&nbsp;Illumina&#8217;s $7.1 billion bid for&nbsp;Grail, stating that they&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/03/37877811/eu-antitrust-regulators-overstepped-in-illumina-grail-deal-says-court-adviser" rel="noreferrer noopener">exceeded their powers</a>.&nbsp;
Following requests from several EU countries, the European Commission invoked Article 22 in 2021 to assess the Illumina-Grail deal despite it falling below the EU merger revenue threshold.&nbsp;
In July, Illumina acquired&nbsp;Fluent BioSciences to expand its reach in single-cell analysis and&nbsp;multiomics research for an&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39716150/whats-going-on-with-10x-genomics-stock-on-wednesday" rel="noreferrer noopener">undisclosed consideration</a>.
Price Action: ILMN stock is up 1.11% at $132.86 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40684403/sanofi-still-bets-on-multiple-sclerosis-med-tolebrutinib-despite-the-investigational-drug-fell-sh" target="_blank" rel="noreferrer noopener">Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials</a>.</li>
</ul>
Photo via Shutterstock

Health Care

Legal

GRAL

European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL.
Today's judgment confirms Illumina's longstanding view that the European Commission exceeded its authority by asserting jurisdiction over this merger. The basis for the 432 million euro fine has now been removed and will no longer be payable.
Following Illumina's spin-off of GRAIL in June 2024, GRAIL is now an independent public company. Illumina maintains a minority share of 14.5% in GRAIL, and Illumina will continue to support the company with its sequencing technology and suite of services.
In the US, the FTC Commissioners dismissed the case against Illumina and GRAIL on August 15, 2024, following the successful spinoff of GRAIL, thus ending the US proceedings.

Government

Regulations

Illumina Hails ECJ Ruling, Eliminates €432M Fine Over GRAIL Acquisition

Illumina's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NYSE">ILMN</a>) short percent of float has fallen 9.67% since its last report. The company recently reported that it has 4.21 million shares sold short, which is 2.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Illumina Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725303620_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Illumina has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Illumina's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Illumina's peer group average for short interest as a percentage of float is 5.44%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Illumina's Recent Short Interest

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 12.08% on an annualized basis producing an average annual return of 20.4%. Currently, Illumina has a market capitalization of $20.98 billion. 
Buying $1000 In ILMN: If an investor had bought $1000 of ILMN stock 20 years ago, it would be worth $42,473.66 today based on a price of $131.70 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724877029_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today

Illumina, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) has secured the FDA&#39;s approval for its in vitro diagnostic (IVD) TruSight Oncology&nbsp;Comprehensive test and first two companion diagnostic (CDx) indications. The test analyses more than 500 genes to profile a patient&#39;s solid tumor, improving the chances of identifying an immuno-oncology or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.
The latest development marks a long-awaited milestone for the company&#39;s oncology customers and community. In Europe, a separate CE-marked version of TSO Comprehensive has been available since its launch in 2022.&nbsp;
<h2>Role of ILMN&#39;s TSO Comprehensive Test as a CDx</h2>
A CDx test can reveal whether a patient&#39;s tumor has a specific gene change or biomarker that can be targeted by a therapy, helping to determine if a patient should receive the treatment. Illumina&#39;s TSO Comprehensive is FDA-approved as a CDx to identify adult and pediatric patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions that may benefit from treatment with Bayer&#39;s VITRAKVI (larotrectinib). VITRAKVI is a highly selective TRK inhibitor approved for use in patients with TRK fusion cancer, in accordance with therapeutic labeling.
NTRK gene fusions are rare across most solid cancer tumor types (~0.1%&ndash;0.3%) and can be challenging to detect, given that these genes can fuse with different partners, many of which were previously unknown. TSO Comprehensive interrogates ribonucleic acid and can identify a broad range of known and novel gene fusion partners across all three NTRK gene fusions, NTRK1, NTRK2 and NTRK3.
Most CDx tests are specific to one type of cancer, however, TSO Comprehensive is approved for use across solid tumor indications for the NTRK CDx. This helps to maximize the chances of finding actionable information from each patient&#39;s biopsy.
<h2>Importance of ILMN&#39;s TSO Comprehensive in NSCLC Treatment</h2>
The test is also approved to identify adult patients with locally advanced or metastatic rearranged during transfection (RET) fusion-positive non-small-cell lung cancer (NSCLC) that may benefit from treatment with Eli Lilly&#39;s RETEVMO (selpercatinib) &mdash; a highly selective and potent RET kinase inhibitor in locally advanced or metastatic NSCLC.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6a/75694.jpg?v=224811459" />
Image Source: Zacks Investment Research
As one of the most common types of lung cancer and the leading cause of cancer-related deaths globally, NSCLC has an expansive actionable biomarker landscape. This has driven the need for broad molecular profiling to better understand the patient&#39;s disease and guide clinical management. The oncogenic activation of RET fusion-positive NSCLC by gene fusions is a primary driver in NSCLC, occurring in up to 2% of cases.
TSO Comprehensive enables broad characterization and simultaneous detection of multiple prognostic and predictive biomarkers such as RET, genomic signatures such as tumor mutational burden and emerging biomarkers within NSCLC in a single test.
<h2>Collaborations Boost Illumina&#39;s Cancer Efforts</h2>
Illumina&#39;s partnerships with industry leaders like Bayer and Lilly are crucial to advancing cancer diagnostics and expanding access to precision oncology for more patients. The company is developing a pipeline of CDx claims through partnerships with pharmaceutical companies, which will be added to TSO Comprehensive following appropriate regulatory approvals. These CDx claims will help unlock groundbreaking targeted therapies and immunotherapies to benefit cancer patients.
TSO Comprehensive will start shipping to customers this year. Comprehensive genomic profiling assays with CDx claims for solid tumors, like TSO Comprehensive, are reimbursable under Centers for Medicare &amp; Medicaid Service national coverage determination.
<h2>Industry Prospects Favors Illumina</h2>
Per a Grand View Research report, the global oncology CDx market was valued at $4.78 billion in 2023 and projected to grow at a compound annual growth rate (CAGR) of 8.7% by 2030.
The market is growing due to the increasing prevalence of cancer, the growing adoption of CDx and a rising emphasis on personalized medicine. The need for early cancer detection tests, which can help improve disease management &amp; reduce mortality, is expected to propel the overall market growth.
<h2>Illumina&#39;s Recent Developments</h2>
Earlier this month, the company expanded its oncology menu for the NovaSeq X Series customers with the high-throughput version of TruSight Oncology 500 and the latest version of its distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2. These assays enable labs to confidently expand oncology testing research of tissue and liquid biopsy samples, with new transformative sequencing economics, faster sequencing run times and broader batch sizes on the NovaSeq X Series for the first time.
<h2>ILMN Stock Price, Consensus and EPS Surprise</h2>
In the past year, ILMN shares have lost 17.2% compared with the industry&#39;s decline of 2.3%.
In the past 30 days, Illumina&#39;s 2024 estimated earnings have surged nearly 94% to $3.16 per share. The stock has beat estimates in each of the trailing four quarters, the average surprise being 463.5%.
<h2>ILMN&#39;s Zacks Rank and Other Top MedTech Stocks</h2>
Illumina currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the broader medical space are Exact Sciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exas#NASDAQ">EXAS</a>), Boston Scientific and SiBone (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sibn#NASDAQ">SIBN</a>), each carrying a Zacks Rank #2 (Buy) at present.
Exact Sciences&#39; shares have lost 25.2% in the past year. Estimates for the company&#39;s loss per share have improved from $1.09 to 95 cents in 2024 and from 26 cents to 6 cents in 2025 in the past 30 days. EXAS&#39; earnings beat estimates in three of the trailing four quarters and matched in one, delivering an average surprise of 56.2%. In the last reported quarter, it posted an earnings surprise of 75.7%.
Estimates for Boston Scientific&#39;s 2024 earnings per share have moved to $2.40 from $2.36 in the past 30 days. Shares of the company have gained 48.1% in the past year compared with the industry&#39;s growth of 13.9%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%. In the last reported quarter, it delivered an earnings surprise of 6.9%.
Estimates for SiBone&#39;s 2024 loss per share have narrowed to 89 cents from 95 cents in the past 30 days. Shares of the company have lost 23% in the past year against the industry&#39;s 11.4% growth. SIBN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
<a href="https://www.zacks.com/stock/news/2328511/ilmn-s-tso-comprehensive-ivd-test-secures-fda-approval-as-cdx?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2328511">To read this article on Zacks.com click here.</a>

SIBN

ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx

Argus Research analyst Jasper Hellweg upgrades Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from Hold to Buy and announces $150 price target.

Upgrades

Argus Research Upgrades Illumina to Buy, Announces $150 Price Target

<ul>
<li>TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims</li>
<li>The 500+ gene biomarker test advances access to localized precision oncology for patients</li>
</ul>
SAN DIEGO, Aug. 27, 2024 /PRNewswire/ --&nbsp;Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro&nbsp;diagnostic (IVD)&nbsp;TruSight&#x2122; Oncology (TSO) Comprehensive test and its first two&nbsp;companion diagnostic (CDx) indications. This single test interrogates over 500 genes to profile a patient's solid tumor, helping to increase the likelihood of identifying&nbsp;an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. TSO Comprehensive is FDA approved as a CDx to identify adult and pediatric patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions that may benefit from treatment with Bayer's VITRAKVI&#xAE; (larotrectinib). The test is also approved to identify adult patients with locally advanced or metastatic rearranged during transfection (RET)&nbsp;fusion-positive non-small-cell lung cancer (NSCLC) that may benefit from treatment with Lilly's RETEVMO&#xAE; (selpercatinib).

FDA Approves Illumina Cancer Biomarker Test With Two Companion Diagnostics To Rapidly Match Patients To Targeted Therapies

Catalyst Watch: Tesla's Robotaxi reveal, AI events for Nvidia, AMD, and HP Enterprise

Revisiting Illumina

The healthcare sector can be a safe haven if volatility increases.

Biotech Stocks Poised For Another Big Move In Q4

UBS' highest and lowest scoring 'quantamental signal' ideas

Illumina introduces new DNA sequencing instruments, but Street unimpressed

Illumina (ILMN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ryskin from Ban...

Illumina Faces Cannibalization Risks and Structural Challenges; Sell Rating Affirmed

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price target o...

RBC Capital Reaffirms Their Buy Rating on Illumina (ILMN)

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Illumina (ILMN – Research Report), with a price target o...

Piper Sandler Sticks to Their Buy Rating for Illumina (ILMN)

In a report released today, Daniel Arias from Stifel Nicolaus maintained a Buy rating on Illumina (ILMN – Research Report), with a price target of ...

Stifel Nicolaus Keeps Their Buy Rating on Illumina (ILMN)

In a report released today, Daniel Brennan from TD Cowen maintained a Buy rating on Illumina (ILMN – Research Report), with a price target of $144....

TD Cowen Sticks to Their Buy Rating for Illumina (ILMN)

ABBV

ABNB

ACCD

AGYS

ALKS

AMZN

ANET

APLD

ARKG

AVGO

BIDU

BYND

CAPR

CBRE

CELH

COST

EBAY

EVRI

FAST

FLUT

GDRZF

GILD

GOOG

GSAT

GWRE

HELE

HSIC

INTC

MNST

MYGN

NAPA

NVDA

NVNO

ODFL

ORCL

PAYX

SAVA

SEDG

SITC

SMAR

SOXX

TMUS

TRGP

TSCO

TSLA

UBER

VLKAF

VSTO

VTNR

ZLDPF

Press Releases

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024

Illumina announces strategy to accelerate value creation

Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG)

FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies

Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology

European Court of Justice rules in favor of Illumina in jurisdictional appeal

Charles Dadswell to step down as General Counsel, Illumina initiates search for successor

Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers

LUDG

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Illumina

Actualités

Dernières nouvelles pour Illumina (NASDAQ:ILMN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL